Baird cuts Sarepta Therapeutics stock price target on growth concerns

Baird cut its Sarepta price target to $18 from $20 and maintained a Neutral rating, citing Elevidys growth concerns and enrollment data that it views as incrementally negative for the outlook. Elevidys revenue was flat in the quarter; third-quarter 2026 revenue of $381.4 million and adjusted EPS of $0.13 beat estimates of $353.25 million and $0.11, respectively, but the stock faced pressure after earnings amid weaker product sales, higher manufacturing costs, and gene-therapy uncertainty. Sarepta reported $1.97 billion in trailing-12-month revenue, down 20% year over year; its next clinical catalyst is MAD data in DM1 and FSHD, expected in Q4 2026.

Analysis

The key issue is conversion, not enrollment: a six-month lag leaves near-term visibility weak, while flat Elevidys sales and PMO-led strength make the reported beat less informative about the product most tied to growth expectations. If conversion remains slow, analysts may need to lower forward revenue assumptions before the competitive pressure expected in the ’51 franchise arrives, creating a risk of estimate cuts and multiple compression. Higher manufacturing costs could amplify that pressure if product mix shifts toward lower-contribution revenue, but the article provides no margin data to quantify it.

Over the next few weeks, the Q4 2026 DM1/FSHD data are the principal asymmetric catalyst: positive results could restore pipeline value, while weak or delayed data would leave the commercial thesis carrying more weight. Over 1–3 months, watch enrollment-to-treatment conversion and product-level sales rather than headline EPS beats. The competitive risk in the ’51 franchise is a 6–18 month issue, not yet proof of lost share.

Contrarian point: a near-spot analyst target is not a valuation floor, and a clinical-data-driven biotech can re-rate sharply despite weak near-term sales. Conversely, platform undervaluation labels do not establish a catalyst or protect against estimate cuts. The bearish thesis is falsified by improving Elevidys sales/conversion, stable or rising forward estimates, or clearly positive clinical data; deterioration in those measures would strengthen it.

Key Decisions for Investors

• Favor a tactical underweight in SRPT versus a broad biotech exposure such as XBI while conversion and product-level growth remain unconfirmed; avoid treating the analyst target as a downside floor.
• For existing SRPT holders, consider reducing exposure or using a defined-risk hedge into the Q4 data catalyst. Check option implied volatility and event pricing first; do not pay an excessive premium for protection.
• Reassess after the next product-level update: improving Elevidys sales and treatment conversion would argue against the underweight, while continued stagnation or further earnings revisions would support maintaining it.
• Track the Q4 DM1/FSHD readouts separately from the commercial thesis; strong data could produce a sharp counter-rally, while delays or weak results remove a potential offset to near-term execution risk.